Astrazeneca plc
Astrazeneca plc (AZN) Covered Calls
Astrazeneca plc trades in the Drug Manufacturers - General industry with an IV Rank of 19.84%, low versus the past year. AZN's highest covered call setup is the $190.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 4.24% out of the money with 3 days to expiration, a 4.30% return until expiration, and a 522.66% theoretical annualized return. Across the setups shown, annualized returns run from 102.64% to 522.66% at strikes between $185.00 and $260.00, with 3 to 150 days to expiration, as of Nov 17, 2026.
Read more
Running AZN covered calls helps you generate income from Astrazeneca plc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AZN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If AZN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AZN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AZN covered call is worth writing.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
| 2026-11-20 | 3 | 190.00 | 4.24 | 0.10 | 0.25 | 783.00 | 4.30 | 522.66 | -0.05 | +0.08 | 692 | 0.15 |
| 2026-11-20 | 3 | 185.00 | 1.50 | 0.90 | 1.20 | 363.00 | 1.99 | 242.31 | -0.49 | +0.31 | 891 | 0.30 |
| 2026-12-18 | 31 | 210.00 | 15.21 | 0.10 | 0.45 | 2783.00 | 15.27 | 179.77 | -0.05 | +0.05 | 281 | 0.35 |
| 2027-01-15 | 59 | 230.00 | 26.19 | 0.05 | 0.30 | 4778.00 | 26.21 | 162.17 | -0.03 | +0.02 | 320 | 0.25 |
| 2027-01-15 | 59 | 220.00 | 20.70 | 0.15 | 0.55 | 3788.00 | 20.78 | 128.57 | -0.08 | +0.05 | 483 | 0.40 |
| 2027-02-19 | 94 | 240.00 | 31.67 | 0.05 | 0.75 | 5778.00 | 31.70 | 123.09 | -0.03 | +0.04 | 14 | 0.70 |
| 2026-12-18 | 31 | 200.00 | 9.73 | 0.55 | 1.00 | 1828.00 | 10.03 | 118.08 | -0.30 | +0.12 | 181 | 0.45 |
| 2027-03-19 | 122 | 250.00 | 37.16 | 0.25 | 0.80 | 6798.00 | 37.30 | 111.58 | -0.14 | +0.04 | 0 | 0.55 |
| 2027-04-16 | 150 | 260.00 | 42.65 | 0.25 | 0.70 | 7798.00 | 42.78 | 104.10 | -0.14 | +0.04 | 0 | 0.45 |
| 2027-02-19 | 94 | 230.00 | 26.19 | 0.45 | 1.10 | 4818.00 | 26.43 | 102.64 | -0.25 | +0.07 | 54 | 0.65 |
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV Rank19.84% Low
- Market cap (M$)277,242
- 52 weeks high-15.96%
- 52 weeks low16.52%
- Analyst recommendationStrong Buy
1.50 - Target price$228.71
27.94% above the current stock price - Dividend—
- Payout ratio47.19%
- Earnings date2027-02-09
- P/E25.30
- Future P/E15.73
- EPS (ttm)7.07
- EPS growth next 5 years11.21%
As of Nov 17, 2026